|Publication number||US4713176 A|
|Application number||US 06/722,800|
|Publication date||Dec 15, 1987|
|Filing date||Apr 12, 1985|
|Priority date||Apr 12, 1985|
|Also published as||DE3689533D1, DE3689533T2, DE3689533T3, EP0218639A1, EP0218639A4, EP0218639B1, EP0218639B2, WO1986005999A1|
|Publication number||06722800, 722800, US 4713176 A, US 4713176A, US-A-4713176, US4713176 A, US4713176A|
|Inventors||Donald W. Schoendorfer, Lee E. Hansen|
|Original Assignee||Hemascience Laboratories, Inc.|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (1), Non-Patent Citations (6), Referenced by (84), Classifications (18), Legal Events (5)|
|External Links: USPTO, USPTO Assignment, Espacenet|
The use of human blood and blood plasma is so widespread that much work has been directed to blood handling systems, including specifically plasmapheresis systems for extraction of plasma from whole blood. While centrifugation was primarily used in the past in preference to membrane filtration techniques, more recent breakthroughs in membrane filtration technology have occurred that are effecting widespread changes. New plasmapheresis systems are based upon the usage of a vortex enhanced fractionation approach which uses a rotating spinner within a shell, with the surface of the spinner or shell being covered with a filtration membrane. Relative velocities and blood flow conditions are established such that constantly sweeping vortices appear along the length of the spinner to continually present fresh plasma to the surface of the membrane while maintaining high shear conditions. This action enables plasma to be filtered through the membrane without depositing cellular or other matter on the membrane surface so as to increasingly clog the pores of the membrane.
A particular example of this type of system is described in a patent application by Donald W. Schoendorfer entitled "Method And Apparatus For Separation Of Matter From Suspension", Ser. No. 591,925, filed Mar. 21, 1984. With rotating spinner devices of this type, substantially higher plasma flow rates per unit of membrane surface area are obtained than with prior membrane systems, enabling the manufacture of low cost disposable filtration units that can extract two or three units of plasma with minimal donor discomfort and time commitment.
In plasmapheresis systems it is necessary to use an anticoagulant in an amount sufficient to minimize blood clotting but below the level at which adverse physiological effects occur. Automated plasmapheresis systems have typically employed from approximately 10% to approximately 4% of known citrate solutions for restricting clotting tendencies.
In operating plasmapheresis systems using a rotating spinner and vortex action, trauma to the blood is low and it is feasible to utilize anticoagulant at the lower end of the permissible range for most donors. Using a membrane of approximately 60 cm3 in area, plasma "take" rates of 35 ml/min are expected, so that a donor time of approximately 30 minutes is established for about 500 ml of blood. This time interval includes, in a single needle system, periodic dwell periods during which the plasmapheresis system returns packed cells to the donor. During these dwell periods no whole blood flows through the plasmapheresis device and the spinner might not be rotated, so that the blood then in the device is in a static or quasi-static condition. During these dwell periods the blood sometimes reacts with the filter. When this reaction occurs the flow rate through the filter is thereafter significantly reduced. Some flow reduction may also occur during the active periods.
Clinical studies and detailed analysis have shown that this flow reduction occurs with a minor percentage of the donor population, approximately 10%. The difference between this subpopulation of donors and the majority of donors is not fully understood, and the problem appears at this time to pose complex problems that will not be easily resolved. It is not currently known, for example, whether the substandard flow condition arises from a constant donor characteristic or is related to diet, physiologicl changes or other time variable factors. Thus there is no way to identify specific members of the subpopulation until they have been coupled into the plasmapheresis system. It is nonetheless desirable to have an essentially standardized system and clinical procedure for the extraction of plasma from the donor population. It is also a fundametal objective to provide a procedure which gives a substantially constant rate of take of plasma or other constituent.
Extensive investigations as to the functional operation of the filtration process did not reveal the reason for the existence of a special subpopulation. Furthermore, review of the literature as to effects of various levels of anticoagulant were not instructive. Although there have been many investigations of biochemical aspects of the coagulation mechanism, these do not clarify the increase in deposition and consequent lowering of filtration rate in a cyclically operated filtration system. Despite the fact that the effects of fluid characteristics such as pH and ion concentration on blood cells have been extensively studied in a non-shear, storage type environment, the effects in a high shear environment have not been well defined.
Plasmapheresis systems and methods in accordance with the invention maintain blood in a cyclically operated membrane filtration system in a specifically anticoagulated condition to achieve substantially standardized plasma flow rates for increased percentages of the donor population despite periodic interruptions in the filtration process. The anticoagulant is maintained within a range sufficient to inhibit the onset of blood clotting, without exceeding a ratio recommended by the U.S. Pharmacopea. At the same time, the pH of the anticoagulated whole blood/plasma is held within the range of 6.8 to 7.2, which appears to diminish blood interaction with the filter. It is surmised that it is the action of "activated" platelets with the surface of the membrane which decreases plasma flow. It is a fact that this decrease in plasma flow occurs after the first separation cycle--during the dwell period when packed cells are being returned to the donor. Concurrently with inhibition of clotting, therefore, the platelets are stabilized against changes of physical characteristics and are prevented from agglutinatin and co-adhesion, which in the minority of the donor population appears to impede plasma flow through the membrane, with a consequent reduction of the plasma flow rate. In a specific example in accordance with the invention, ACD-A anticoagulant having a starting pH of 4.6 is mixed with the whole blood in a ratio of 1:12.5 ACD-A to anticoagulated whole blood. The blood is pumped from a donor into a rotating vortex enhanced type of plasmapheresis system in which vortex flow is maintained. Plasma flow rates for an entire donor population are attained which are equal to or greater than 35 ml/min for the entire extraction cycle.
A better understanding of the invention may be held by reference to the following description, taken in conjunction with the accompanying drawings, in which:
FIG. 1 is a combined block diagram and perspective view of a plasmapheresis system in accordance with the invention; and
FIG. 2 is a graphical depiction of plasma flow rates with respect to time in operation of a typical system.
In a plasmapheresis system and method in accordance with the invention, referring now to FIG. 1, a membrane filtration system 10 comprises a cylindrical body 12 within which a spinner or rotor 14 covered by a membrane 15 is driven remotely, as by a magnetic drive 16, at a selected rotational velocity, here 3600 r.p.m. In the fashion described in the previously referenced Schoendorfer application, whole blood is directed into the space between the rotor 14 and housing 12 from an input port 20. A helical continuity of internally circulating cells is established about the surface of the rotor 14 by virtue of the relationship between rotor diameter, angular velocity, flow gap dimension and blood viscosity. Plasma is continually filtered through the surface of the membrane 15 into channels (not shown) on the surface and in the interior of the rotor 14, from which it passes downwardly, in this instance, to a plasma filtrate outlet port 22. The packed cell remainder fluid is transferred through an outlet port 24 to a reservoir 26, from which it is periodically pumped for return to the donor.
Although a double needle system may be utilized, it is much more typical, for patient comfort, to employ a single needle 30, feeding whole blood from the donor under the impetus of a peristaltic input pump 32 into the inlet port 20. Anticoagulant is concurrently combined with the input whole blood. The anticoagulant is taken from an anticoagulant source 36 at a rate controlled by a separate anticoagulant pump 37. Plasma from the plasma outlet port 22 is fed directly to a plasma collection bag 40, usually simply under gravity flow. To reinfuse packed cells via the single needle, however, a return pump 42 is coupled between the reservoir 26 and the needle 30. A level sensor 43 (a mass sensor may alternatively be used) in a control system 44 (shown only generally) signals a sequence controller 45, such as a microprocessor, when the blood reservoir is full. The full signal activates the return pump 42 during dwell intervals in the plasma extraction cycle. Concurrently, the input pump 32 and anticoagulant pump 37 are stopped and the magnetic drive 16 and rotor 14 are shifted to a lower rotational rate, such as 600 r.p.m. Details of the control system 44 have been omitted for simplicity and brevity inasmuch as they may take many forms including manual on-off actuation of the various pumps.
The proportion of anticoagulant from the source 36 is determined in this system by the anticoagulant pump 37 which is operated to deliver anticoagulant at a selectably controllable rate relative to the whole blood input flow. The plasma collection bag 40 is large enough to receive the entire plasma quantity (e.g. 500 ml of anticoagulated plasma).
Operation of the plasmapheresis system of FIG. 1 presents unique problem because, as seen in FIG. 2, the whole blood which is disposed about the rotor is subjected to alternate conditions of operation. To obtain approximately 500 ml of anticoagulated plasma, a packed cell reservoir 26 of approximately 140 ml capacity is typically used, together with a blood flow rate at approximately 40 hematocrit of 100 ml/min. In the normal donor population, as shown in solid lines in FIG. 2, this results in a filtration cycle of approximately 21/2 minutes, with packed cells being delivered to the reservoir 26 at 65 ml/min as 35 ml/min of plasma are delivered to the collection bag 40. For approximately the next two minutes a reinfusion cycle completes the extraction-reinfusion sequence. During the reinfusion cycle the rotor 14 is slowed down to 600 r.p.m. to maintain the vortex condition in the blood about the rotor 14, as the collected packed cells are reinfused in the donor via the return pump 42 and the single needle 30. As indicated by dotted lines in FIG. 2, however, the 10% subpopulation of donors introduces a hitherto unexplained and uncorrectable degradation of performance. After the forced dwell interval, the plasma take is substantially lowered, and thereafter decreases further. This means that the filtration cycles are terminated more quickly because the packed cell concentrate output rate is higher. Consequently, a greater number of cycles, and therefore a greater amount of donor time, are required to collect the desired total amount of plasma.
It is not feasible, according to numerous studies relative to blood collection and storage and donor reaction to anticoagulant to utilize an anticoagulant/blood ratio of >1:6. Furthermore, anticoagulant per se is not a controlling factor in decreased plasma flow, because evidence of coagulation is not observed in the plasma or in the returned packed cells. Evidently the reduced plasma flow is due to some form of deposition at the membrane surface.
The inventors have determined, however, that the changing dynamic conditions of blood flow giving rise to the deposition problem can be fully and effectively counteracted in the great majority of the donor population by the usage of, for example, ACD-A anticoagulant having pH in the range of 4.5 to 5.5 (preferably 4.5 to 4.8) and in a proportion sufficient to lower the normal blood/plasma pH, typically 7.38, to the range of 6.8 to 7.2. This condition is maintained during all of the filtration cycles, thus carrying over to the dwell cycles in which some whole blood is entrapped between the rotor 14 and the encompassing housing. The ratio of anticoagulant to whole blood is maintained in a range of 1:6 to 1;25 to attain adequate suppression of coagulation while avoiding adverse effects in the donor.
Analysis of the literature for an explanation of this phenomenon has not revealed a basis for full understanding. In the short term handling of platelets in available anticoagulants, for period of less than approximately 24 hours, no specific anticoagulant expendients have been regarded as necessary to prevent the onset of aggregation of the platelets into larger masses. Thus, inasmuch as the blood is constantly in motion in the present system except during the dwell periods, like reasoning should apply. In longer term storage of platelets than for 24 hours, it has been found beneficial to maintain control of the acidity of the blood constituents so as to be essentially neutral, as shown by the following articles:
Murphy, S. and Gardner, F., "Platelet Storage at 22° C.: Role of Gas Transport Across Plastic Containers in Maintenance of Viability", Blood, Vol. 46, 209, 1975.
Schlicter, S., "Preservation of Platelet Viability and Function During Storage of Concentrates", The Blood Platelet in Transfusion Therapy, Alan R. Liss Inc., N.Y., 83-100, 1978.
Murphy, S. et al, "Storage of Platelets at 22° C.:, Blood, Vol. 35, 549, 1970.
Rock, G. and Figuerdo, A., "Metabolic Changes During Platelet Storage", Transfusion, Vol. 16, 571, 1976.
Molone, S. et al, "Platelet Storage at 22° C. . . .", Blood, Vol. 52, 425, 1978.
Koerner, K, "Platelet Function After Shipment of Room Temperature Platelet Concentrates", Vox Sang, 44, 37, 1983.
Lysaght, M. et al, "Transport Considerations in Flat Sheet Microporous Membrane Plasmapheresis", Plasma Therapy Transfusion Technology, 4, 373, 1983.
These disclosures provide a basis for conjecture as to the mechanism involved in achieving the desired rate of deposition for virtually all donors using the present plasmapheresis system. As previously indicated, however, there is no understanding at this time of the mechanism which causes the 10% donor subpopulation to interrelate differently with the machine than the majority of donors and no useful test for initially identifying members of the donor subpopulation. It is surmised, however, that the dynamic forces acting on the blood during the initial filtration cycle are substantially different from those acting on the blood during the dwell cycle and that the platelets, although constantly being recirculated in vortices during the relatively short dwell interval, gradually change in characteristics. This change may be expressed as an alteration from normal discoid shape to spherical and even to a pseudopodal, many armed shape having more adherent surface characteristics, but this is though to be symptomatic of primary causative factors rather than an initiating factor itself. The change is more likely, but still without certainty, due to an imbalance or revised distribution of ionic or other surface charges, whether hydrogen ions alone (pH) or total ions (pK). Whatever the cause, the sequence appears to be reversible on a short term basis by the reintroduction of new pH stabilized whole blood. Consequently, although the initial phases of platelet agglutination may be occurring in the donor subpopulation during and after the first dwell interval, creating a deposit or overlayer of agglutinated platelets on the membrane, stabilization of the ionic balance or other causative factors results in the reversible change, dissolving the deposited structure and enabling a return to the desired filtrate take rate for plasma.
The presence of sufficient anticoagulant in solution in the blood makes available citrate which chelates calcium in the blood and prevents activation of the clotting mechanism. However, the level of anticoagulant must, as previously noted, be limited to no greater than 1:6, and preferably is kept as low as possible (e.g. 1:25) for beneficial return to the donor and minimal dilution of the desired blood product. An advantage of the spinning rotor type of system is that the vortices and flow rates can be substantial but the internal circulation of blood insures that no sharp projections are encountered. Consequently, the blood is not substantially traumatized and tendencies to coagulate are kept low, so that in consequence substantial anticoagulant is not needed.
The incipient tendency toward agglutination on the surface of the filtration membrane, therefore, can be well controlled in this type of system by using an acceptacle range (1:6 to 1:25) of anticoagulant, where the anticoagulant has an initially low enough pH range to bring the blood/plasma pH down to the preferred 6.8 to 7.2 range. Clinical tests on hundreds of patients, using ACD-A anticoagulant in a 1:12.5 ratio, have shown a marked decrease in the percentage of donors (from more than 10% to about 11/2%) as to whom the low plasma take problem arises, in comparison to prior conventional anticoagulant formulations. Repeated tests on specific donors whose plasma take falls off with tri-sodium citrate anticoagulant in an acceptable concentration have also demonstrated that normal plasma flux rates are attained in most of the affected donor subpopulation using the procedures of the present invention.
For example, a number of individuals were first identified whose characteristics, given an anticoagulant blood/plasma pH of 7.2 or higher, gave a plasma flow of less than 27 ml/min at the end of the second withdrawal cycle. These individuals were anticoagulated with tri-sodium citrate or ACD-A, had normal hematocrits (44% to 47%) and were giving blood input flow rates of 100 ml/min. Using anticoagulant of sufficient quantity (e.g. 1:10) and sufficiently low starting pH (e.g. 4.6), the plasma flows at the end of the second cycle were in each instance brought into the 36-40 ml/min range.
Whether the onset of agglutination occurs during the filtration interval or during a dwell interval must at this point remain conjectural, but it appears quite clearly that platelet shape changes are reversibly controlled and that tendencies toward buildup or unification of platelet masses are avoided. It is recognized, however, that internal platelet changes may occur during these intervals, and that degranulation, or the emission of internal components of the platelets in the performance of normal functions, may be taking place.
While there have been described above and illustrated in the drawings various forms and modifications of concepts in accordance with the invention, it will be appreciated that the invention is not limited thereto but encompasses all examples and variants within the scope of the appended claims.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US3634228 *||Oct 22, 1969||Feb 7, 1984||Title not available|
|1||*||Dorson, Int. App. WO82/03567, 10 1982.|
|2||Dorson, Int. App. WO82/03567, 10-1982.|
|3||Forstron et al, "Formed Element Deposition onto Filtering Walls", Trans. Am. Soc. Artif. Int. Organs, vol. XXI (1975) (pp. 602-607(.|
|4||*||Forstron et al, Formed Element Deposition onto Filtering Walls , Trans. Am. Soc. Artif. Int. Organs, vol. XXI (1975) (pp. 602 607(.|
|5||*||Lopez Leiva, Ultrafiltration at Low Degrees of Concentration Polarization: Technical Possibilities , Dec. 80, pp. 210 651.|
|6||Lopez-Leiva, "Ultrafiltration at Low Degrees of Concentration Polarization: Technical Possibilities", Dec. 80, pp. 210-651.|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US4790942 *||Jun 10, 1987||Dec 13, 1988||Membrex Incorporated||Filtration method and apparatus|
|US4808307 *||Feb 16, 1988||Feb 28, 1989||Haemonetics Corporation||Couette membrane filtration apparatus for separating suspended components in a fluid medium using high shear|
|US4876013 *||Feb 26, 1988||Oct 24, 1989||Membrex Incorporated||Small volume rotary filter|
|US4900440 *||Jun 14, 1988||Feb 13, 1990||Sulzer Brothers Limited||Dynamic pressure filter|
|US4911847 *||Dec 16, 1987||Mar 27, 1990||Membrex, Inc.||Process for controlling the permeate composition in a rotary filtration device|
|US4935002 *||Jun 29, 1988||Jun 19, 1990||Biodynamics, Inc.||Apparatus and method for the autotransfusion of blood|
|US4944883 *||Oct 11, 1988||Jul 31, 1990||Schoendorfer Donald W||Continuous centrifugation system and method for directly deriving intermediate density material from a suspension|
|US4968600 *||Mar 13, 1987||Nov 6, 1990||Toray Industries, Inc.||Apparatus for separating cell suspension|
|US5000848 *||Sep 6, 1989||Mar 19, 1991||Membrex, Inc.||Rotary filtration device with hyperphilic membrane|
|US5013446 *||Apr 25, 1990||May 7, 1991||Y. T. Li Engineering, Inc.||Chromatographic gel contactor and process|
|US5053127 *||May 21, 1990||Oct 1, 1991||William F. McLaughlin||Continuous centrifugation system and method for directly deriving intermediate density material from a suspension|
|US5188588 *||Dec 20, 1989||Feb 23, 1993||Baxter Internatonal Inc.||Single needle continuous hemapheresis apparatus and methods|
|US5234608 *||Dec 11, 1990||Aug 10, 1993||Baxter International Inc.||Systems and methods for processing cellular rich suspensions|
|US5242384 *||Mar 13, 1992||Sep 7, 1993||Davol, Inc.||Blood pumping and processing system|
|US5263924 *||Sep 25, 1991||Nov 23, 1993||Baxter International Inc.||Integrated low priming volume centrifugal pump and membrane oxygenator|
|US5423738 *||Sep 7, 1993||Jun 13, 1995||Robinson; Thomas C.||Blood pumping and processing system|
|US5464534 *||Oct 12, 1993||Nov 7, 1995||William F. McLaughlin||Blood fractionation system and method|
|US5614106 *||Jun 2, 1995||Mar 25, 1997||Baxter International Inc.||Method and apparatus for collection of platelets|
|US5639382 *||Jun 7, 1995||Jun 17, 1997||Baxter International Inc.||Systems and methods for deriving recommended storage parameters for collected blood components|
|US5676841 *||Jun 7, 1995||Oct 14, 1997||Baxter International Inc.||Blood processing systems and methods which monitor citrate return to the donor|
|US5681273 *||Jun 7, 1995||Oct 28, 1997||Baxter International Inc.||Systems and methods for predicting blood processing parameters|
|US5690835||Sep 24, 1996||Nov 25, 1997||Baxter International Inc.||Systems and methods for on line collection of cellular blood components that assure donor comfort|
|US5730883 *||Jun 7, 1995||Mar 24, 1998||Baxter International Inc.||Blood processing systems and methods using apparent hematocrit as a process control parameter|
|US5759413 *||Jun 7, 1995||Jun 2, 1998||Baxter International Inc.||Systems and method for estimating platelet counts using a spleen mobilization function|
|US5762791 *||Aug 9, 1995||Jun 9, 1998||Baxter International Inc.||Systems for separating high hematocrit red blood cell concentrations|
|US5833866 *||Feb 26, 1997||Nov 10, 1998||Baxter International Inc.||Blood collection systems and methods which derive instantaneous blood component yield information during blood processing|
|US6007725||Nov 21, 1997||Dec 28, 1999||Baxter International Inc.||Systems and methods for on line collection of cellular blood components that assure donor comfort|
|US6059979 *||Oct 30, 1997||May 9, 2000||Baxter International Inc.||Blood processing systems and methods using apparent hematocrit as a process control parameter|
|US6080322 *||May 5, 1998||Jun 27, 2000||Baxter International Inc.||Systems and methods for separating high hematocrit red blood cell concentrations|
|US6099730 *||Nov 13, 1998||Aug 8, 2000||Massachusetts Institute Of Technology||Apparatus for treating whole blood comprising concentric cylinders defining an annulus therebetween|
|US6197202||Feb 23, 1998||Mar 6, 2001||Baxter International Inc.||Systems and methods for estimating platelet counts using a spleen mobilization function|
|US6207063||Mar 16, 2000||Mar 27, 2001||Baxter International Inc.||Blood processing systems and methods using apparent hematocrit as a process control parameter|
|US6251284||Nov 26, 1997||Jun 26, 2001||Baxter International Inc.||Systems and methods which obtain a uniform targeted volume of concentrated red blood cells in diverse donor populations|
|US6277556||Dec 17, 1998||Aug 21, 2001||Baxter International Inc.||Controlling donor blood characteristics|
|US6451203||Feb 23, 2001||Sep 17, 2002||Baxter International Inc.||Blood processing systems and methods using apparent hematocrit as a process of control parameter|
|US6464624||Jun 12, 2001||Oct 15, 2002||Haemonetics Corporation||Blood processing method and apparatus using a centrifugation bowl with filter core|
|US6527957||Apr 7, 1999||Mar 4, 2003||Baxter International Inc.||Methods for separating, collecting and storing red blood cells|
|US6629919||Jan 18, 2001||Oct 7, 2003||Haemonetics Corporation||Core for blood processing apparatus|
|US6736768||Nov 2, 2001||May 18, 2004||Gambro Inc||Fluid separation devices, systems and/or methods using a fluid pressure driven and/or balanced approach|
|US6773389||Nov 2, 2001||Aug 10, 2004||Gambro Inc||Fluid separation devices, systems and/or methods using a fluid pressure driven and/or balanced configuration|
|US6802982||Sep 11, 2002||Oct 12, 2004||Baxter International Inc.||Blood processing systems and methods using red blood cell hematocrit as a process control parameter|
|US7094196||Mar 29, 2004||Aug 22, 2006||Gambro Inc.||Fluid separation methods using a fluid pressure driven and/or balanced approach|
|US7094197||Apr 12, 2004||Aug 22, 2006||Gambro, Inc.||Method for fluid separation devices using a fluid pressure balanced configuration|
|US7166231||Jan 9, 2003||Jan 23, 2007||Baxter International Inc.||Red blood cell separation method|
|US7208091 *||Jun 26, 2001||Apr 24, 2007||Bio Gasol Ipr Aps||Assembly for withdrawing and filtering partial volumes of process fluid|
|US7297272||Apr 19, 2004||Nov 20, 2007||Fenwal, Inc.||Separation apparatus and method|
|US7789245||Aug 3, 2009||Sep 7, 2010||Fenwal, Inc.||Blood separation chamber|
|US7918350||Mar 6, 2009||Apr 5, 2011||Fenwal, Inc.||Separation apparatus and method|
|US8075468||Feb 27, 2009||Dec 13, 2011||Fenwal, Inc.||Systems and methods for mid-processing calculation of blood composition|
|US8123713||Apr 24, 2009||Feb 28, 2012||Caridian Bct, Inc.||System and method for collecting plasma protein fractions from separated blood components|
|US8202240||Apr 24, 2009||Jun 19, 2012||Caridianbct, Inc.||System and method for collecting plasma protein fractions from separated blood components|
|US8454548||Apr 14, 2008||Jun 4, 2013||Haemonetics Corporation||System and method for plasma reduced platelet collection|
|US8535421||Oct 8, 2010||Sep 17, 2013||New Health Sciences, Inc.||Blood storage bag system and depletion devices with oxygen and carbon dioxide depletion capabilities|
|US8569052||May 25, 2011||Oct 29, 2013||New Health Sciences, Inc.||Oxygen depletion devices and methods for removing oxygen from red blood cells|
|US8647289||Mar 31, 2011||Feb 11, 2014||Haemonetics Corporation||System and method for optimized apheresis draw and return|
|US8685258||Feb 27, 2009||Apr 1, 2014||Fenwal, Inc.||Systems and methods for conveying multiple blood components to a recipient|
|US8702637||Apr 14, 2008||Apr 22, 2014||Haemonetics Corporation||System and method for optimized apheresis draw and return|
|US8808217||May 2, 2013||Aug 19, 2014||Haemonetics Corporation||System and method for plasma reduced platelet collection|
|US8808978||Nov 15, 2010||Aug 19, 2014||Haemonetics Corporation||System and method for automated platelet wash|
|US8828226||Apr 14, 2009||Sep 9, 2014||The Trustees Of Boston University||System for assessing the efficacy of stored red blood cells using microvascular networks|
|US8834402||Mar 12, 2009||Sep 16, 2014||Haemonetics Corporation||System and method for the re-anticoagulation of platelet rich plasma|
|US8852140 *||Jan 6, 2012||Oct 7, 2014||Fenwal, Inc.||System and method for adjustment of blood separation procedure parameters|
|US9005150 *||Jul 18, 2011||Apr 14, 2015||Baxter International Inc.||Flow balancing system and method, especially for citrate|
|US9005343||Aug 10, 2012||Apr 14, 2015||New Health Sciences, Inc.||Integrated leukocyte, oxygen and/or CO2 depletion, and plasma separation filter device|
|US9067004||Mar 28, 2012||Jun 30, 2015||New Health Sciences, Inc.||Method and system for removing oxygen and carbon dioxide during red cell blood processing using an inert carrier gas and manifold assembly|
|US9095662||Aug 16, 2013||Aug 4, 2015||New Health Sciences, Inc.||Blood storage bag system and depletion devices with oxygen and carbon dioxide depletion capabilities|
|US9199016||Jul 3, 2012||Dec 1, 2015||New Health Sciences, Inc.||System for extended storage of red blood cells and methods of use|
|US9248227||Aug 14, 2014||Feb 2, 2016||Haemonetics Corporation||System and method for the re-anticoagulation of platelet rich plasma|
|US9296990||Sep 26, 2013||Mar 29, 2016||New Health Sciences, Inc.||Oxygen depletion devices and methods for removing oxygen from red blood cells|
|US9302042||Jun 20, 2013||Apr 5, 2016||Haemonetics Corporation||System and method for collecting platelets and anticipating plasma return|
|US9339025||Aug 25, 2011||May 17, 2016||New Health Sciences, Inc.||Method for enhancing red blood cell quality and survival during storage|
|US9364600||Jan 29, 2014||Jun 14, 2016||Haemonetics Corporation||System and method for optimized apheresis draw and return|
|US20030160007 *||Jun 26, 2001||Aug 28, 2003||Pind Peter Frode||Assembly for withdrawing and filtering partial volumes of process fluid|
|US20050148991 *||May 21, 2003||Jul 7, 2005||Johnson Douglas G.||Device for using patient blood as diluent in administering pharmaceuticals|
|US20100042037 *||Apr 24, 2009||Feb 18, 2010||Caridianbct, Inc.||System and Method for Collecting Plasma Protein Fractions from Separated Blood Components|
|US20100042038 *||Apr 24, 2009||Feb 18, 2010||Caridianbct, Inc.||System and Method for Collecting Plasma Protein Fractions from Separated Blood Components|
|US20110146146 *||Dec 10, 2010||Jun 23, 2011||Harwood Edward D||Method and apparatus for aeroponic farming|
|US20110266221 *||Jul 18, 2011||Nov 3, 2011||Baxter Healthcare S.A.||Flow balancing system and method, especially for citrate|
|US20120175313 *||Jan 6, 2012||Jul 12, 2012||Barry Jr John W||System and method for adjustment of blood separation procedure parameters|
|WO1989004690A1 *||Nov 22, 1988||Jun 1, 1989||Baxter International Inc.||Single needle continuous hemapheresis apparatus and methods|
|WO1991001787A1 *||Jul 26, 1990||Feb 21, 1991||Y.T. Li Engineering, Inc.||Chromatographic gel contactor and process|
|WO1991001796A1 *||Jul 26, 1990||Feb 21, 1991||Y.T. Li Engineering, Inc.||Orbital/oscillation filtration system with no rotary seal|
|WO1997005938A1 *||May 22, 1996||Feb 20, 1997||Baxter International Inc.||Systems and methods for separating erythrocytes|
|WO2013023156A1||Aug 10, 2012||Feb 14, 2013||New Health Sciences, Inc.||Integrated leukocyte, oxygen and/or co2 depletion, and plasma separation filter device|
|U.S. Classification||210/645, 210/321.68, 210/782|
|International Classification||A61M1/02, A61M1/26, A61M1/30, A61M1/00, A61M1/36, A61M1/34|
|Cooperative Classification||A61M1/3496, A61M1/3672, A61M1/3693, A61M1/30, A61M1/303, A61M1/265, A61M1/308|
|European Classification||A61M1/36H, A61M1/30|
|Apr 12, 1985||AS||Assignment|
Owner name: HEMASCIENCE LABORATORIES, INC., A CORP. OF CA.
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:SCHOENDORFER, DONALD W.;HANSEN, LEE E.;REEL/FRAME:004397/0555
Effective date: 19850402
|Jul 29, 1987||AS||Assignment|
Owner name: BAXTER TRAVENOL LABORATORIES, INC., DEERFIELD, ILL
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:HEMASCIENCE LABORATORIES, INC., A CA CORP.;REEL/FRAME:004769/0367
Effective date: 19870722
Owner name: BAXTER TRAVENOL LABORATORIES, INC.,ILLINOIS
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HEMASCIENCE LABORATORIES, INC., A CA CORP.;REEL/FRAME:004769/0367
Effective date: 19870722
|Apr 1, 1991||FPAY||Fee payment|
Year of fee payment: 4
|Apr 3, 1995||FPAY||Fee payment|
Year of fee payment: 8
|Jun 14, 1999||FPAY||Fee payment|
Year of fee payment: 12